

2013-2014 Special Projects: Pharmacogenomics Websites

Name of Pharmacogenomic Resource						
SECONDARY RESOURCES						
ASHP Pharmacogenomics Resource Page	http://www.ashp.org/menu/PracticePolicy/ResourceCenters/Emerging-Sciences/Pharmacogenomics.aspx	2013	Association	Some articles open, some require subscription	Compendium	The American Society of Health-System Pharmacists site provides links to multiple resources on pharmacogenomics, including articles and books, training modules, and presentations from ASHP meetings. Links to external resources are also provided.
Advancing Pharmacogenomics in Pharmacy Practice	http://www.aphafoundation.org/AM/CM/ContentDisplay.cfm?ContentFileID=7960&MicrositeID=0&FusePreview=Yes	2012	Association	Open	White Paper	This paper outlines a strategic plan to advance the science of pharmacogenomics into pharmacy practice.
Therapeutic drug monitoring and pharmacogenetics interface considerations	http://guideline.gov/content.aspx?f=rss&id=15665	2010	Government	Open	Guideline	U.S. Department of Health & Human Services National Guideline Clearinghouse summary of therapeutic drug monitoring and pharmacogenomic considerations in clinical practice. This summary highlights major recommendations in the practice guidelines for pharmacogenomics application in laboratory medicine and also provides links to other summary documents.
Integrating	http://www.pharma	2011	Association	Open	Whitepaper	American Pharmacists Association

2013-2014 Special Projects: Pharmacogenomics Websites

Name of Pharmacogenomic Resource						
Pharmacogenomics into Pharmacy Practice via Medication Therapy Management	cist.com/sites/default/files/files/mtm_integrating_pharmacogenomics.pdf					document exploring the application and integration of pharmacogenomics in pharmacy clinical practice via medication therapy management.
Pharmacotherapy - Special Article on Pharmacogenomics in Pharmacy Benefit Management	http://www.ncbi.nlm.nih.gov/pubmed/22392418	2012	Journal	Requires subscription	Journal Article	This article discusses how pharmacogenomics can be applied in a benefit coverage policy and clinical programs. Also discusses future opportunities for pharmacogenomics in pharmacy benefit management.
American Medical Association brochure on pharmacogenomics	http://www.ama-assn.org/resources/doc/genetics/pgx-brochure-2011.pdf	2011	Association	Open	Brochure	The American Medical Association provides an overview of pharmacogenomics and highlights several drugs: abacavir, codeine, clopidogrel, and warfarin.
The Pharmacogenomics Journal	http://www.nature.com/tpj/index.html	2013	Publishing Group	Some articles open, some require subscription	Journal	Journal that publishes articles on new research related to pharmacogenomics, such as newly discovered genes important to drug metabolism or toxicity.
What is pharmacogenomics?	http://ghr.nlm.nih.gov/handbook/genomicresearch/pharmacogenomics	2013	Government	Open	Handbook	<p>This site provides basic information about pharmacogenomics and how genes work. Site sponsored by the U.S. National Library of Medicine.</p> <p>Has links to an interactive tutorial, a list of clinical trials involving pharmacogenomics, and more.</p>

2013-2014 Special Projects: Pharmacogenomics Websites

Name of Pharmacogenomic Resource						
Human Genome Project Information - Pharmacogenomics	http://www.ornl.gov/sci/techresources/Human_Genome/medicine/pharma.shtml	2011	Government	Open	FAQs	<p>Provides information about the Human Genome Project (HGP). Site sponsored by the U.S. Department of Energy.</p> <p>Has links to ethical/legal issues, medicine, education, gene gateway, research archive, gene testing, gene therapy, pharmacogenomics, genetic counseling, and disorders.</p>
AMCP Format for Formulary Submissions Version 3.1	http://amcp.org/practice-resources/amcp-format-formulary-submissions.pdf	2012	Association	Open	Guideline	<p>Companion Diagnostics Addendum (Pages 21-26) provides drug and companion diagnostic test (CDT) developers with guidance for the provision of clinical and economic evidence in health technology assessments and informs drug and CDT manufacturers, P&T committees, Medical Technology Assessment committees, and other coverage and reimbursement decision-makers about appropriate types of evidence for a CDT so that well-informed evaluations can be performed.</p>